secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-09-23T23:59:59+00:00
Accession:  0001437749-25-029721
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025
--------------------------------------------------------------------------------

- Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
- Q4 net revenue $15.1M (+4% YoY); net loss $19.8M vs $4.6M prior year (incl. $18.1M impairment and derivative losses).
- ADHD Portfolio net revenue $57.6M (flat YoY); Pediatric Portfolio $8.8M (+20% YoY).
- Cash $31.0M at June 30, 2025; 9th consecutive quarter of positive adjusted EBITDA.
- EXXUA (gepirone) for MDD launch on track for Q4 2025; entering >$22B US MDD market with novel first-in-class agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925029721/0001437749-25-029721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925029721/aytu20250514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer